Lucentis in DME: so far so good

Article

Ranibizumab (Lucentis; Novartis) is an effective treatment for diabetic macular oedema (DME), according to Peter Campochiaro, MD, from the Department of Ophthalmology, Wilmer Eye Institute, USA, speaking at the Retina Subspecialty Day.

Ranibizumab (Lucentis; Novartis) is an effective treatment for diabetic macular oedema (DME), according to Peter Campochiaro, MD, from the Department of Ophthalmology, Wilmer Eye Institute, USA, speaking at the Retina Subspecialty Day.

Twenty patients with chronic macular oedema were enrolled in a Phase I trial. Inclusion criteria included a foveal thickness of 250 microns or greater, vision of 20/40 to 20/320, no laser treatment during the previous three months, no periocular or intraocular steroids for four months or anti-angiogenic treatment for 12 months. The study design called for an intravitreal injection of 0.5 mg of ranibizumab at baseline and at one, two, four and six months. The primary end-point was month seven and the patients were followed for one year.

Dr Campochiaro used the the optical coherence tomography scans of two patients to demonstrate the results. "The response to ranibizumab was rapid," he reported. "One week after the first injection, there was marked improvement in the foveal thickening. In one patient the improvement remained for the duration of the trial; in the second patient, there was an initial improvement one week after injection, but the improvement deteriorated over one and two months with the development of substantial macular oedema."

All twenty patients responded to ranibizumab, but the pattern of the response differed among patients. The improvement in the mean excess foveal thickness at the primary end point was about 87%, an improvement that Dr Campochiaro described as "dramatic."

Even one year after treatment, there was still substantial improvement in the foveal thickness. At the primary end point, the median improvement in foveal thickness was 300 microns, a 97% improvement. The mean improvement in visual acuity was 10 letters.

"Six months after the last treatment, there was still significant improvement compared with baseline, raising the following questions: What is the appropriate interval for the injections? What are the long-term effects of the treatment? Is there any benefit to combining this treatment with laser treatment?" Dr Campochiaro posed.

A Phase II trial is planned.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Related Content
© 2025 MJH Life Sciences

All rights reserved.